Hormonal factors and the risk of breast cancer according to estrogen- and progesterone-receptor subgroup
- PMID: 14578142
Hormonal factors and the risk of breast cancer according to estrogen- and progesterone-receptor subgroup
Abstract
Evidence suggests hormonal factors may be more strongly associated with estrogen receptor+progesterone receptor+ (ER+PR+) than ER-PR- breast cancer risk. This study evaluated risk factors according to ERPR tumor status among pre- and postmenopausal women participating in two recent population-based case-control studies. Breast cancer cases, ages 25-74 years, and diagnosed 1995-1998 were sampled from the Ontario Cancer Registry. Controls were a random sample of women identified using the Ontario Ministry of Finance rolls and were frequency-matched to cases within 5-year age groups. Epidemiological data were collected from breast cancer cases and controls using two self-administered questionnaires. ERPR data were obtained for 87% of the breast cancer cases (3,276 of 3,748). Multivariate polytomous logistic regression was used to obtain odds ratios estimates and 95% confidence intervals. The following significant differences were observed in the risk factor profiles for ER+PR+ and ER-PR- breast cancer: among premenopausal women, late age at menarche was only associated with a reduction in ER+PR+ breast cancer risk; obesity was associated with an increased ER-PR- and decreased ER+PR+ cancer risk; and the association between alcohol intake and breast cancer risk was heterogeneous across ERPR subgroups, although the direction varied across the levels of alcohol intake. Among postmenopausal women, there were no statistically significant differences observed in the risk factor profiles for ER+PR+ and ER-PR- breast cancer. Some heterogeneity exists in the risk factor profiles of ER+PR+ and ER-PR- premenopausal breast cancer; however, risk factor profiles did not differ markedly for postmenopausal breast cancer.
Similar articles
-
Phytoestrogen intake from foods, during adolescence and adulthood, and risk of breast cancer by estrogen and progesterone receptor tumor subgroup among Ontario women.Int J Cancer. 2013 Apr 1;132(7):1683-92. doi: 10.1002/ijc.27788. Epub 2012 Sep 14. Int J Cancer. 2013. PMID: 22907507
-
Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study.J Natl Cancer Inst. 2005 Nov 2;97(21):1601-8. doi: 10.1093/jnci/dji341. J Natl Cancer Inst. 2005. PMID: 16264180
-
Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies.Cancer Epidemiol Biomarkers Prev. 2000 Jul;9(7):681-7. Cancer Epidemiol Biomarkers Prev. 2000. PMID: 10919738
-
Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis.Breast Cancer Res Treat. 2010 Oct;123(3):641-9. doi: 10.1007/s10549-010-1116-4. Epub 2010 Aug 15. Breast Cancer Res Treat. 2010. PMID: 20711809 Review.
-
Etiology of hormone receptor-defined breast cancer: a systematic review of the literature.Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1558-68. Cancer Epidemiol Biomarkers Prev. 2004. PMID: 15466970 Review.
Cited by
-
Incorporating tumour pathology information into breast cancer risk prediction algorithms.Breast Cancer Res. 2010;12(3):R28. doi: 10.1186/bcr2576. Epub 2010 May 18. Breast Cancer Res. 2010. PMID: 20482762 Free PMC article.
-
Oral Contraceptive Use and Breast Cancer Risk According to Molecular Subtypes Status: A Systematic Review and Meta-Analysis of Case-Control Studies.Cancers (Basel). 2022 Jan 23;14(3):574. doi: 10.3390/cancers14030574. Cancers (Basel). 2022. PMID: 35158842 Free PMC article. Review.
-
Oral contraceptive use and estrogen/progesterone receptor-negative breast cancer among African American women.Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):2073-9. doi: 10.1158/1055-9965.EPI-10-0428. Epub 2010 Jul 20. Cancer Epidemiol Biomarkers Prev. 2010. PMID: 20647407 Free PMC article.
-
The obesity-inflammation-eicosanoid axis in breast cancer.J Mammary Gland Biol Neoplasia. 2013 Dec;18(3-4):291-307. doi: 10.1007/s10911-013-9299-z. Epub 2013 Oct 30. J Mammary Gland Biol Neoplasia. 2013. PMID: 24170420 Review.
-
Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women.Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2078-86. doi: 10.1158/1055-9965.EPI-08-0206. Epub 2008 Jul 29. Cancer Epidemiol Biomarkers Prev. 2008. PMID: 18664548 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials